List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 24.5. Medicines for disorders due to psychoactive substance use |
Others observations: The medicines should only be used within an established support programme. Therapeutic alternatives: buprenorphine |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 24.5. Medicines for disorders due to psychoactive substance use |
Others observations: The medicines should only be used within an established support programme. Therapeutic alternatives: buprenorphine |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 24.5. Medicines for disorders due to psychoactive substance use |
Others observations: The medicines should only be used within an established support programme. Therapeutic alternatives: buprenorphine |
List | Section | Observation |
---|---|---|
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain. |
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 24.5. Medicines for disorders due to psychoactive substance use |
Others observations: The medicines should only be used within an established support programme. Therapeutic alternatives: buprenorphine |
List | Section | Observation |
---|---|---|
Bolivia | LINAME 2011 - 2013 | No observations |
Colombia | 8.0 Toxicology | No observations |
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
Training CSamouge 2022 | 2.2 Opioid analgesics |
Others observations: For the management of cancer pain. |
WHO Model List of Essential Medicines (2021) | 2.2. Opioid analgesics |
Others observations: For the management of cancer pain. |